English   español  
Por favor, use este identificador para citar o enlazar a este item: http://hdl.handle.net/10261/114271
Compartir / Impacto:
Estadísticas
Add this article to your Mendeley library MendeleyBASE
Citado 27 veces en Web of Knowledge®  |  Pub MebCentral Ver citas en PubMed Central  |  Ver citas en Google académico
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL
Exportar otros formatos: Exportar EndNote (RIS)Exportar EndNote (RIS)Exportar EndNote (RIS)
Título

Chemokine receptor-specific antibodies in cancer immunotherapy: achievements and challenges

Autor Vela, María; Aris, Mariana; Llorente, Mercedes; García-Sanz, José A. ; Kremer, Leonor
Palabras clave Chemokine receptors
Therapeutic antibodies
Clinical trials
Immunotherapy
Cancer
Fecha de publicación 30-ene-2015
EditorFrontiers Media
Citación Frontiers in Immunology. Immunotherapies and Vaccines, January 2015, 6 (12)
ResumenThe 1990s brought a burst of information regarding the structure, expression pattern, and role in leukocyte migration and adhesion of chemokines and their receptors. At that time, the FDA approved the first therapeutic antibodies for cancer treatment. A few years later,it was reported that the chemokine receptors CXCR4 and CCR7 were involved on directing metastases to liver, lung, bone marrow, or lymph nodes, and the over-expression of CCR4, CCR6, and CCR9 by certain tumors. The possibility of inhibiting the interaction of chemokine receptors present on the surface of tumor cells with their ligands emerged as a new therapeutic approach. Therefore, many research groups and companies began to develop small molecule antagonists and specific antibodies, aiming to neutralize signaling from these receptors. Despite great expectations, so far, only one anti-chemokine receptor antibody has been approved for its clinical use, mogamulizumab, an anti-CCR4 antibody, granted in Japan to treat refractory adult T-cell leukemia and lymphoma. Here, we review the main achievements obtained with anti-chemokine receptor antibodies for cancer immunotherapy, including discovery and clinical studies, proposed mechanisms of action, and therapeutic applications.
Descripción 15 p.-2 tab.
Versión del editorhttp://dx.doi.org/ 10.3389/fimmu.2015.00012
URI http://hdl.handle.net/10261/114271
DOI10.3389/fimmu.2015.00012
ISSN1664-3224
E-ISSN1664-3224
Aparece en las colecciones: (CIB) Artículos
Ficheros en este ítem:
Fichero Descripción Tamaño Formato  
fimmu_García Sanz_2015.pdf533,69 kBAdobe PDFVista previa
Visualizar/Abrir
Mostrar el registro completo
 



NOTA: Los ítems de Digital.CSIC están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.